{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:34:58Z","timestamp":1773084898047,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015439","name":"Centres de Recerca de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.12.038","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T02:42:16Z","timestamp":1608864136000},"page":"687-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["RTS,S\/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-4768","authenticated-orcid":false,"given":"Roger","family":"Suau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Ruiz-Olalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"V\u00e1zquez-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjerai","family":"Jairoce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto J.","family":"Nhabomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dosoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwaku Poku","family":"Asante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Owusu-Agyei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-9874","authenticated-orcid":false,"given":"Luis","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross L.","family":"Coppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-9549","authenticated-orcid":false,"given":"Virander","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetij","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Beeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-9836","authenticated-orcid":false,"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-4060","authenticated-orcid":false,"given":"Carlota","family":"Doba\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.12.038_b0005","unstructured":"World Health Organisation. World malaria report 2019; 2019."},{"key":"10.1016\/j.vaccine.2020.12.038_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-032713-120220","article-title":"Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease","volume":"32","author":"Crompton","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pt.2015.11.015","article-title":"Malaria parasites in the asymptomatic: looking for the hay in the haystack","volume":"32","author":"Galatas","year":"2016","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ijpara.2017.05.004","article-title":"IgG opsonization of merozoites: multiple immune mechanisms for malaria vaccine development","volume":"47","author":"Hill","year":"2017","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0025","doi-asserted-by":"crossref","first-page":"eaax4489","DOI":"10.1126\/sciadv.aax4489","article-title":"IgM in human immunity to Plasmodium falciparum malaria","volume":"5","author":"Boyle","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2020.12.038_b0030","first-page":"139","article-title":"The natural occurrence of circulating antibodies in populations of endemic malarious areas","volume":"27","author":"Biswas","year":"1990","journal-title":"Indian J Malariol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4269\/ajtmh.2000.62.373","article-title":"Contrasting functions of IgG and IgE antimalarial antibodies in uncomplicated and severe Plasmodium falciparum malaria","volume":"62","author":"Troye-Blomberg","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.12.038_b0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.1877","article-title":"The function of immunoglobulin A in immunity","volume":"208","author":"Woof","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0045","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1172\/JCI14397","article-title":"Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb","volume":"109","author":"Feng","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.12.038_b0050","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/emmm.201201929","article-title":"IgA EGFR antibodies mediate tumour killing in vivo","volume":"5","author":"Boross","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0055","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.1003189","article-title":"A novel human IgA monoclonal antibody protects against tuberculosis","volume":"186","author":"Balu","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0060","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1128\/IAI.69.8.4846-4850.2001","article-title":"Immunoglobulin A-Mediated Protection against Bordetella pertussis Infection","volume":"69","author":"Hellwig","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0065","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI6310","article-title":"Killing of Streptococcus pneumoniae by capsular polysaccharide\u2013specific polymeric IgA, complement, and phagocytes","volume":"104","author":"Janoff","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.12.038_b0070","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.4049\/jimmunol.166.10.6250","article-title":"Activity of Human IgG and IgA Subclasses in Immune Defense Against Neisseria meningitidis Serogroup B","volume":"166","author":"Vidarsson","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0075","doi-asserted-by":"crossref","first-page":"2001526","DOI":"10.1183\/13993003.01526-2020","article-title":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients","volume":"56","author":"Yu","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2020.12.038_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study","volume":"507","author":"Padoan","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.vaccine.2020.12.038_b0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-3024.2009.01101.x","article-title":"Fc-receptors and immunity to malaria: from models to vaccines","volume":"31","author":"Pleass","year":"2009","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and Fc\u03b1RI: pathological roles and therapeutic opportunities","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02703849","article-title":"Naturally occurring plasmodium-specific IgA antibody in humans from a malaria endemic area","volume":"20","author":"Biswas","year":"1995","journal-title":"J Biosci"},{"key":"10.1016\/j.vaccine.2020.12.038_b0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1475-2875-7-186","article-title":"Pattern of humoral immune response to Plasmodium falciparum blood stages in individuals presenting different clinical expressions of malaria","volume":"7","author":"Leoratti","year":"2008","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.12.038_b0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1472-6750-11-77","article-title":"The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1\u201319 (PfMSP119)","volume":"11","author":"Shi","year":"2011","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0115","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-019-04822-7","article-title":"Erythrocyte binding ligand region VI specific IgA confers tissue protection in malaria infection","author":"Deore","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.vaccine.2020.12.038_b0120","doi-asserted-by":"crossref","first-page":"e107903","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2020.12.038_b0125","doi-asserted-by":"crossref","unstructured":"First Results of Phase 3 Trial of RTS,S\/AS01 Malaria Vaccine in African Children. N Engl J Med 2011;365:1863\u20131875. doi: 10.1056\/NEJMoa1102287.","DOI":"10.1056\/NEJMoa1102287"},{"key":"10.1016\/j.vaccine.2020.12.038_b0130","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31\u201345. doi: 10.1016\/S0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2020.12.038_b0135","doi-asserted-by":"crossref","unstructured":"A Phase 3 Trial of RTS,S\/AS01 Malaria Vaccine in African Infants. N Engl J Med 2012;367:2284\u201395. doi: 10.1056\/NEJMoa1208394.","DOI":"10.1056\/NEJMoa1208394"},{"key":"10.1016\/j.vaccine.2020.12.038_b0140","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS, S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0145","doi-asserted-by":"crossref","unstructured":"Krishna S editor. Efficacy and Safety of the RTS,S\/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites, PLoS Med. 11 (2014) e1001685. doi: 10.1371\/journal.pmed.1001685.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"10.1016\/j.vaccine.2020.12.038_b0150","doi-asserted-by":"crossref","unstructured":"Ballou WR, Cohen J. Malaria vaccines. In: Vaccines, Elsevier, 2013. p. 1133\u201337. doi: 10.1016\/B978-1-4557-0090-5.00056-2.","DOI":"10.1016\/B978-1-4557-0090-5.00056-2"},{"key":"10.1016\/j.vaccine.2020.12.038_b0155","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.vaccine.2018.01.069","article-title":"S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype","volume":"36","author":"Nielsen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.038_b0160","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS, S\/AS01E malaria vaccine efficacy","volume":"10","author":"Doba\u00f1o","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12916-018-1186-4","article-title":"Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS, S\/AS01E vaccination in African children","volume":"16","author":"Ubillos","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0170","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.038_b0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12916-019-1378-6","article-title":"RTS, S\/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study","volume":"17","author":"Doba\u00f1o","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0180","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","article-title":"Systems analysis of protective immune responses to RTS, S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2020.12.038_b0185","doi-asserted-by":"crossref","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","article-title":"Mapping functional humoral correlates of protection against malaria challenge following RTS, S\/AS01 vaccination","volume":"12","author":"Suscovich","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00439","article-title":"Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS, S Vaccination","volume":"10","author":"Doba\u00f1o","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0195","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1038\/s41598-018-28325-w","article-title":"Antibody responses to \u03b1-Gal in African children vary with age and site and are associated with malaria protection","volume":"8","author":"Aguilar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.12.038_b0200","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.cell.2014.10.053","article-title":"Gut Microbiota Elicits a Protective Immune Response against Malaria Transmission","volume":"159","author":"Yilmaz","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.12.038_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00498-16","article-title":"The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines","volume":"85","author":"Espinosa","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-4347(01)00340-1","article-title":"Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Escherichia coli","volume":"762","author":"Kolodny","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.vaccine.2020.12.038_b0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1126\/science.1827210","article-title":"Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein","volume":"252","author":"Khusmith","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.12.038_b0220","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/IAI.72.9.5135-5142.2004","article-title":"Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria","volume":"72","author":"John","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0225","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.vaccine.2017.09.027","article-title":"Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel\u00ae in European and African adults: A phase 1a\/1b, randomized, double-blind multi-centre trial","volume":"35","author":"Sirima","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.038_b0230","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.1300444","article-title":"Erythrocyte-Binding Antigens of Plasmodium falciparum Are Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity","volume":"191","author":"Persson","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0235","doi-asserted-by":"crossref","first-page":"17861","DOI":"10.1074\/jbc.271.30.17861","article-title":"Identification and Characterization of the Protective Hepatocyte Erythrocyte Protein 17 kDa Gene of Plasmodium yoelii, homolog of Plasmodium falciparum Exported Protein 1","volume":"271","author":"Doolan","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.12.038_b0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0166-6851(96)02826-5","article-title":"Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1","volume":"85","author":"Cavanagh","year":"1997","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0245","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1074\/jbc.M113.520239","article-title":"Plasmodium falciparum Merozoite Surface Protein 3","volume":"289","author":"Imam","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.12.038_b0250","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1128\/IAI.67.5.2075-2081.1999","article-title":"Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum","volume":"67","author":"Black","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0255","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1128\/IAI.00145-16","article-title":"Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity","volume":"84","author":"Hill","year":"2016","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0260","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.4049\/jimmunol.1001555","article-title":"Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum Malaria","volume":"185","author":"Reiling","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045253","article-title":"The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria","volume":"7","author":"Reiling","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.038_b0270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/IAI.00970-13","article-title":"Bacterially Expressed Full-Length Recombinant Plasmodium falciparum RH5 Protein Binds Erythrocytes and Elicits Potent Strain-Transcending Parasite-Neutralizing Antibodies","volume":"82","author":"Reddy","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.038_b0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jim.2018.01.009","article-title":"Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens","volume":"455","author":"Vidal","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.12.038_b0280","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/jcm.32.3.839-840.1994","article-title":"Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test","volume":"32","author":"Jauhiainen","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0285","unstructured":"R.C. Team. R: A language and environment for statistical computing; 2019. https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.vaccine.2020.12.038_b0290","unstructured":"Wickham H, Hester J, Chang W. devtools: Tools to Make Developing R Packages Easier; 2019. https:\/\/cran.r-project.org\/package=devtools."},{"key":"10.1016\/j.vaccine.2020.12.038_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005165","article-title":"Insights into Long-Lasting Protection Induced by RTS, S\/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children","volume":"4","author":"Guinovart","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.038_b0300","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0166-6851(90)90085-Z","article-title":"Cross-reactive asparagine-rich determinants shared between several blood-stage antigens of Plasmodium falciparum and the circumsporozoite protein","volume":"40","author":"Ardeshir","year":"1990","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012557","article-title":"MIG and the Regulatory Cytokines IL-10 and TGF-\u03b21 Correlate with Malaria Vaccine Immunogenicity and Efficacy","volume":"5","author":"Dunachie","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.038_b0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0169-4758(99)01562-8","article-title":"Maintaining the immunological balance in parasitic infections: a role for TGF-beta?","volume":"16","author":"Omer","year":"2000","journal-title":"Parasitol Today"},{"key":"10.1016\/j.vaccine.2020.12.038_b0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1043-4666(03)00049-8","article-title":"Modulation of immune response in Plasmodium falciparum malaria: role of IL-12, IL-18 and TGF-\u03b2","volume":"21","author":"Musumeci","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2020.12.038_b0325","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.4049\/jimmunol.1300161","article-title":"What Is and What Should Always Have Been: Long-Lived Plasma Cells Induced by T Cell-Independent Antigens","volume":"190","author":"Bortnick","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0330","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.actatropica.2010.08.012","article-title":"Blood stage Plasmodium falciparum antigens induce T cell independent immunoglobulin production via B cell activation factor of the TNF family (BAFF) pathway","volume":"116","author":"Kumsiri","year":"2010","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2020.12.038_b0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1590\/0037-8682-0046-2016","article-title":"Frequency of anti- Toxoplasma gondii IgA, IgM, and IgG antibodies in high-risk pregnancies, in Brazil","volume":"49","author":"Murata","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2020.12.038_b0340","doi-asserted-by":"crossref","first-page":"e0161231","DOI":"10.1371\/journal.pone.0161231","article-title":"Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.038_b0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1051\/parasite\/2016012","article-title":"Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB\/c mice","volume":"23","author":"Wang","year":"2016","journal-title":"Parasite"},{"key":"10.1016\/j.vaccine.2020.12.038_b0350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/exer.1999.0678","article-title":"Monoclonal IgA Antibodies Protect Against Acanthamoeba Keratitis","volume":"69","author":"Leher","year":"1999","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.vaccine.2020.12.038_b0355","first-page":"723","article-title":"Natural infection of baboons by Entamoeba histolytica elicits anti- gal-lectin heavy subunit IgA and IgG antibodies with shared epitope specificity to that of humans","volume":"43","author":"Abd-Alla","year":"2013","journal-title":"J Egypt Soc Parasitol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0360","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1139\/w01-004","article-title":"IgA and IgM anti-Naegleria fowleri antibodies in human serum and saliva","volume":"47","author":"Rivera","year":"2001","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.vaccine.2020.12.038_b0365","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.12.038_b0370","article-title":"Multifunctional Antibodies Are Induced by the RTS, S Malaria Vaccine and Associated With Protection in a Phase 1\/2a Trial","author":"Kurtovic","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.038_b0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","article-title":"Induction and decay of functional complement-fixing antibodies by the RTS, S malaria vaccine in children, and a negative impact of malaria exposure","volume":"17","author":"Kurtovic","year":"2019","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20316066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20316066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:46Z","timestamp":1759402366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20316066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20316066"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RTS,S\/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}